个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lihui Wei[1] * ; Yingying Su[2] * ; Yuemei Hu[4] ; Rongcheng Li[5] ; Wen Chen[3] ; Qinjing Pan[3] ; Xun Zhang[3] ; Fanghui Zhao[3] ; Yuqian Zhao[3] ; Qing Li[6] ; Ying Hong[7] ; Chao Zhao[1] ; Mingqiang Li[8] ; Wenyu Liu[9] ; Caihong Li[10] ; Dongping Guo[11] ; Lidong Ke[12] ; Bizhen Lin[13] ; Zhijie Lin[13] ; Shu Chen[2] ; Wei Sheng[2] ; Zizheng Zheng[2] ; Sijie Zhuang[2] ; Fengcai Zhu[4] ; Huirong Pan[13] ; Yimin Li[13] ; Shoujie Huang[2] ; Jun Zhang[2] ; Youlin Qiao[3,*2] ; Ting Wu[2,*1] ; Ningshao Xia[2] ;
机构： [1]Peking University People's Hospital, Beijing ,China [2]the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian ,China [3]National Cancer Center, National Center for Cancer Clinical Research, the Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing ,China [4]Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu ,China [5]Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China [6]Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong，China [7]the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China [8]Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China [9]Funing Center for Disease Control and Prevention, Funing, Jiangsu,China [10]Xinmi Maternal and Child Health Hospital, Xinmi, Henan,China [11]Yangcheng Maternal and Child Health Hospital, Yangcheng, Shanxi,China [12]Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei ,China [13]Xiamen Innovax Biotech Company, Xiamen, Fujian,China
出处：
DOI： 10.1016/j.cmi.2019.12.010
ISSN：

关键词： age distribution human papillomavirus neutralizing antibodies

摘要：
Data from clinical trials of human papillomavirus (HPV) vaccines showed that women naïve (negative for both type-specific antibodies and DNA) to vaccine types would derive benefit from vaccination; therefore, an understanding of the proportion of naïve women in different age groups is important for developing HPV vaccination strategies. From November 2012 to April 2013, a total of 7372 healthy women aged 18-45 years were recruited in five provinces in China. Cervical specimens and serum samples were collected for each woman at entry. Cervical specimens were first tested by the HPV DNA enzyme immunoassay method; if positive, the specimens were then tested by reverse hybridization line probe assay and HPV-16 and HPV-18 specific polymerase chain reactions. Neutralizing antibodies against HPV-16 or HPV-18 were tested with a pseudovirion-based neutralization assay. The overall prevalence of high-risk HPV DNA was 14.8% (1088/7367, 95% CI 14.0-15.6), and the seroprevalence of neutralizing antibodies against HPV-16 and HPV-18 was 12.6% (925/7367) and 4.9% (364/7367), respectively. In younger women (18-26 years) and middle-aged women (27-45 years), 83.8% (3116/3719) and 81.4% (2968/3648) were naïve to both HPV-16 and HPV-18 (both neutralizing antibodies and DNA were negative), respectively. In addition, 98.5% (3664/3719) and 98.0% (3575/3648) of the younger or middle-aged women were naïve to at least one HPV type (HPV-16 or HPV-18). This study revealed that the majority of Chinese women aged 18-26 years and 27-45 years were naïve to both HPV-16 and HPV-18 and would thus derive full benefit from bivalent HPV vaccination. Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

基金：
National Natural Science Foundation of China(81673240); Major Infectious Disease Project of China (2018ZX10101001-002); theScientific Research Foundation of State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics (2018ZY001); and Xiamen Innovax
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 2 区 医学
小类 | 2 区 传染病学 2 区 微生物学
最新[2025]版：
大类 | 2 区 医学
小类 | 1 区 传染病学 2 区 微生物学
JCR分区：
出版当年[2018]版：
Q1 MICROBIOLOGY Q1 INFECTIOUS DISEASES
最新[2023]版：
Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者机构： [1]Peking University People's Hospital, Beijing ,China
共同第一作者：
通讯作者：
通讯机构： [2]the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian ,China [3]National Cancer Center, National Center for Cancer Clinical Research, the Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing ,China [*1]the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics，School of Public Health, Xiamen University, Xiamen 361102, Fujian, China [*2]Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South, Panjiayuan Lane, Beijing 10021, PR China.
推荐引用方式(GB/T 7714)：
Lihui Wei,Yingying Su,Yuemei Hu,et al.Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.[J].CLINICAL MICROBIOLOGY AND INFECTION.2020,26(8):1069-1075.doi:10.1016/j.cmi.2019.12.010.
APA：
Lihui Wei,Yingying Su,Yuemei Hu,Rongcheng Li,Wen Chen...&Ningshao Xia.(2020).Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial..CLINICAL MICROBIOLOGY AND INFECTION,26,(8)
MLA：
Lihui Wei,et al."Age distribution of human papillomavirus infection and neutralizing antibodies in healthy Chinese women aged 18-45 years enrolled in a clinical trial.".CLINICAL MICROBIOLOGY AND INFECTION 26..8(2020):1069-1075

相关文献

[1]缺血性卒中住院患者年龄特征与头颈部大动脉病变分布的多中心研究结果分析 [2]Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity. [3]紫草抗人乳头瘤病毒作用的研究 [4]Development of a quantum dot-based lateral flow immunoassay strip for rapid and sensitive detection of SARS-CoV-2 neutralizing antibodies [5]Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants [6]Treatment of condylomata acuminata caused by low-risk human papillomavirus with chloroquine phosphate gel [7]Human papillomavirus prevalence and integration status in tissue samples of bladder cancer in Chinese population. [8]Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants [9]重组人干扰素α－2b栓联合光动力疗法治疗宫颈人乳头瘤病毒亚临床感染62例疗效评价 [10]人乳头瘤病毒52型E2和E6/E7在宫颈病变中的表达及其意义

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号